NYSE : FMS

Fresenius Medical Care AG & Co. KGaA

$25.66 USD

-$0.04 (-0.16%)

Volume
473.85K
Average Volume
768.71K
Market Capitalization
$13.78B
P/E Ratio
13.55
Dividend Yield
3.35%
Price Target
$19.90
Year High
$27.64
Year Low
$20.02
Day High
—
Day Low
—
Payout Ratio
$0.45
Current Ratio
$1.20
Company Overview

NYSE

Helen Giza

Medical - Care Facilities

Healthcare

FMS

108165

DE

USD

https://www.freseniusmedicalcare.com

49 6172 608 2522

358029106

0001333141

Liquidity Metrics

0.83

1.20

0.86

0.18

0.45

Sales & Valuation

$19.63B

0.62

0.92

6.69

3.24

Profitability

$1.68

$978.37M

4.88%

7.59%

7.16%

3.00%

P/E Metrics

13.55

0.25

0.25

Analyst Price Target & Rating

$19.90

$19.90

$19.90

Neutral

3/5

20 Analysts

28.94%

Financial Health Scores

1.83

8/9

$1.38B

$31.47B

$17.26B

$1.85B

Key Metrics (TTM)

$21.73B

1.12

6.26

1.20

7.16%

5.76%

7.72%

14.96%

$60.96

109 days

Company Executives
Name Title
Charles Hugh-Jones Global Chief Medical Officer & Member of Management Board
Dominik Heger Executive Vice President and Head of Investor Relations, Strategic Development & Communications
Jorg Haring Member of the Management Board, Global Head of Legal,Compliance & Human Resources and Labor Director
Wolfgang Kummerle Senior Vice President - Quality Management International
Craig Cordola FACHE Chief Executive Officer of Care Delivery & Member of Management Board
Joachim Weith Senior Vice President of Corporate Communications & Governmental Affairs
Joseph E. Turk Jr. Chief Executive Officer of Care Enablement & Member of Management Board
Martin Fischer Chief Financial Officer & Member of the Management Board
Helen Giza Chair of Management Board & Chief Executive Officer
Glenn Slater Senior Vice President of Manufacturing and Supply Chain Operations
Gail-Suzanne Brown Senior Vice President of Research & Development
Poll Results

No votes yet today — be the first to share your view!

About Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Stock

Fresenius Medical Care AG & Co. KGaA specializes in comprehensive kidney dialysis treatment and associated services, operating across Germany, North America, and numerous international territories. Through an extensive network of outpatient clinics, it delivers essential dialysis therapy along with laboratory and diagnostic support. For home-based care, the company supplies necessary equipment, provides comprehensive training, and offers ongoing patient assistance, including clinical oversight and coordinating supply deliveries directly to patients. In the United States, Fresenius Medical Care also contracts with hospitals to provide vital dialysis interventions for hospitalized individuals suffering from end-stage renal disease (ESRD) and acute kidney failure. Beyond services, it is a pro ... minent developer, manufacturer, and distributor of a broad range of dialysis products. This portfolio encompasses polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers and solutions, concentrates, bloodlines, renal pharmaceuticals, and water treatment systems. Additionally, the company produces non-dialysis medical devices, including acute cardiopulmonary and apheresis products. Its pharmaceutical division focuses on developing, acquiring, and in-licensing specialized renal medications, distributing these essential drugs and supplies to both individual patients' homes and dialysis centers. The company also extends its medical offerings to include a variety of specialized services such as vascular, cardiovascular, and endovascular care, operating ambulatory surgery centers for vascular procedures, and providing physician services in nephrology and cardiology. Products are sold directly to dialysis clinics, hospitals, and specialized treatment centers, complemented by sales through local teams, independent distributors, dealers, and agents. By February 23, 2022, Fresenius Medical Care managed an impressive network of 4,171 outpatient dialysis clinics across roughly 150 countries. Established in 1996, the company maintains its headquarters in Bad Homburg, Germany.

Hikma and Fresenius best positioned from Trump's generic drug tariffs, says Citi

2026-07-23 09:35:07

Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) and Fresenius Medical Care (NYSE:FMS) could emerge as relative winners from Donald Trump's proposed tariffs on generic drugs because of their extensive US manufacturing operations, according to Citi. The US president this week announced plans to impose a 100% tariff on imported generic medicines from August 2028, rising to 200% a year later.

Ryder Reports Second Quarter 2026 Results

2026-07-23 07:00:00

Ryder System, Inc. (NYSE: R) reported results for the three months ended June 30 as follows: This press release features multimedia. View the full release her

Fresenius Medical Care: More Favorable Patient Outcomes Will Drive Growth

2026-07-21 09:32:08

Fresenius Medical Care has significant growth potential, driven by catalysts including new product rollouts and potentially improved patient outcomes. FMS's Care Delivery segment shows solid underlying earnings growth, with potential upside if patient outcomes continue to improve. Key risks include the expiration of €80M/quarter CMS incentive payments by the end of 2026 and possible stagnation in Care Enablement external sales.

Fresenius Medical: High Yield, Utilities-Like Stock At Valuation Lows

2026-07-11 05:28:48

FMS is a defensive dialysis services provider with stable and recurring demand and regulated pricing. Profitability is recovering as FME25+ cost savings flow through the business. The stock offers attractive shareholder returns through high free cash flow, dividends, and large buybacks.

Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now

2026-07-08 15:05:27

FMS??? margin gains, HighVolumeHDF rollout and AI-driven care are boosting momentum, but reimbursement and volume risks remain.

DVA vs. FMS: Which Dialysis Leader Is Better Positioned Now?

2026-06-23 14:21:09

DaVita and Fresenius Medical Care are taking different paths in kidney care, but which stock offers stronger upside now? Let's dive in.

Focus Graphite Announces SEDAR+ Filing of the NI 43-101 Technical Report with the Updated Mineral Resource for the Lac Tetepisca Project

2026-06-22 05:00:00

One of the Largest Identified Graphite Deposits Globally with 120.2 Mt Indicated at 10.27% Cg and 24.1 Mt Inferred at 9.88% Cg, Containing 14.7 Mt of In-Situ Graphite Ottawa, Ontario--(Newsfile Corp. - June 22, 2026) - Focus Graphite Inc. (TSXV: FMS) (OTCQB: FCSMF) (FSE: FKC0) ("Focus" or the "Company"), a Canadian developer of high-grade flake graphite deposits and advanced graphite materials for battery, defence, and industrial applications, is pleased to announce that it has filed the report on SEDAR+ for the upgraded mineral resource estimate ("MRE") on its 100%-owned Lac Tetepisca Project (the "Project") in Quebec. The Project lies within the Nitassinan (ancestral land) of the Pessamit Innu First Nation of Betsiamites, Quebec.

Focus Graphite Completes Final Major ESIA Technical Study, Advancing Lac Knife Toward Permitting

2026-06-15 05:00:00

Hydrogeological Assessment Concludes Multi-Year Environmental Program and Supports Upcoming ESIA Submission Ottawa, Ontario--(Newsfile Corp. - June 15, 2026) - Focus Graphite Inc. (TSXV: FMS) (OTCQB: FCSMF) (FSE: FKC0) ("Focus" or the "Company") a Canadian developer of high-grade flake graphite deposits and advanced graphite materials for battery, defence, and industrial applications, is pleased to announce the completion of the Hydrogeological Assessment (the "Assessment" or the "Study") for its wholly-owned Lac Knife Graphite Project ("Lac Knife" or the "Project"), concluding a multi-year environmental program and completing the major technical work required to support the Company's Environmental and Social Impact Assessment ("ESIA") submission. Completed by Yves Leblanc, P.Geo.

Frequently Asked Questions

What is the current Fresenius Medical Care AG & Co. KGaA (FMS) stock price?

Fresenius Medical Care AG & Co. KGaA(NYSE:FMS) stock price is $25.66 in the last trading session. During the trading session, FMS stock reached the peak price of $27.64 while $20.02 was the lowest point it dropped to. The percentage change in FMS stock occurred in the recent session was --0.16% while the dollar amount for the price change in FMS stock was -$0.04.

FMS's industry and sector of operation?

The NYSE listed FMS is part of Medical - Care Facilities industry that operates in the broader Healthcare sector.

Who are the executives of FMS?

Charles Hugh-Jones | Global Chief Medical Officer & Member of Management Board
Dominik Heger | Executive Vice President and Head of Investor Relations, Strategic Development & Communications
Jorg Haring | Member of the Management Board, Global Head of Legal,Compliance & Human Resources and Labor Director
Wolfgang Kummerle | Senior Vice President - Quality Management International
Craig Cordola FACHE | Chief Executive Officer of Care Delivery & Member of Management Board

How many employees does FMS have?

Number of FMS employees currently stands at 108165. FMS operates from Else-KrOener Strasse 1, Bad Homburg, HE 61352, DE.

Link for FMS official website?

Official Website of FMS is: https://www.freseniusmedicalcare.com

How do I contact FMS?

FMS could be contacted at phone #49 6172 608 2522 and can also be accessed through its website. FMS operates from Else-KrOener Strasse 1, Bad Homburg, HE 61352, DE.

How many shares of FMS are traded daily?

The average number of FMS shares traded daily for last 3 months was 768.71K.

What is the market cap of FMS currently?

The market value of FMS currently stands at $13.78B with its latest stock price at $25.66